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INTRODUCTION
Among the genetic alterations described in Mantle Cell Lymphoma (MCL) cells are those that involve p53, CDK4, CDKN2A, MYC, BCL2, B cell receptor (BCR) and NFκB signaling genes [1] [2] [3] . These genetic alterations confer a cell autonomous pro-growth and pro-survival advantage on the MCL cells, which is especially dependent on NFκB, BCL2 and MYC activities [2] [3] [4] . Next generation sequencing (NGS) has also disclosed new targets for therapeutic intervention in the deregulated molecular signaling through B cell receptor (BCR), Toll-like receptor (TLR), NOTCH, NF-κB and MAPK signaling pathways in the For personal use only. on July 15, 2017 . by guest www.bloodjournal.org From MCL cell lines and patient-derived primary MCL 3, [4] [5] [6] [7] . Pre-clinical and clinical studies have shown that ibrutinib, a selective, orally bioavailable, irreversible inhibitor of BTK in the BCR, also inhibits NFκB activity, and is active against B-cell neoplasms, including CLL and MCL 6, 8 . Ibrutinib has demonstrated impressive clinical efficacy and is approved for the treatment of CLL and MCL [9] [10] [11] . Despite its high level of clinical activity, primary or acquired clinical resistance to ibrutinib therapy is commonly observed [11] [12] [13] [14] . Similar to what has been described in CLL cells, a cysteine-to-serine (C481S) mutation in BTK at the binding site of ibrutinib, which results in a protein that is only reversibly inhibited by ibrutinib, has also been documented in MCL patients that relapsed while on ibrutinib [12] [13] [14] . However, none of these ibrutinib-resistance associated mutations were detectable in the primary pre-ibrutinib treatment MCL tumor samples 15 . Instead, mutations in MLL2, CREBBP, PIM1 and ERB4 were detected in the ibrutinib-refractory MCL cells 13, 15 . Additionally, as compared to the cell lines sensitive to ibrutinib exhibiting chronic activity of the classical NFκB signaling pathway, ibrutinib-resistant MCL cell lines and primary MCL cells exhibited mutations in TRAF2/3 and MAP3K14 (NIK), activating the alternative NFκB signaling, which would still show dependency on the NFκB-activated 'transcriptome'
for growth and survival 7, 16 . The deregulated transcriptome in these cells would also be governed by the genetic alterations and epigenetic mechanisms that control the expressions of MYC, BCL2 and the G1 checkpoint proteins 3, 7, 16, 17 .
Acetylation-deacetylation of the histone proteins regulates the transcriptome in transformed cells 18 . The
BET (bromodomain and extra-terminal) family of 'reader' proteins, including BRD2 (bromodomain 2), BRD3 and BRD4 recognize and bind to the acetylated lysine residues on the histone proteins associated with the open, transcriptionally permissive chromatin through their N-terminal double, tandem, 110 amino acids-long bromodomains [19] [20] [21] . BET proteins also contain the extra terminal (ET) proteininteracting domain in the C-terminus which assembles a complex of co-regulatory proteins at the enhancers and promoters thereby regulating gene transcription 20, 21 . The C-terminal PID domain (pTEFb interacting domain) of BRD4 interacts with and recruits the pTEFb (positive transcription elongation factor b) to the 'super-enhancers' and promoters, thereby regulating the activity of RNA pol II (RNAP2) and gene expressions of important MCL-relevant oncogenes [21] [22] [23] [24] . Among these are MYC, CDK4/6, cyclin D1 and BCL-2, which control the proliferation and survival of MCL cells [22] [23] [24] . pTEFb, which is a heterodimer composed of cyclin T and CDK9, phosphorylates Ser-2 on the heptad repeats of the CTD in the stalled RNAP2 at the transcriptional start sites, enabling the pause-release of RNAP2 and inducing productive mRNA transcript elongation 24,25-27 . Thus, by promoting the availability of active pTEFb, BRD4 couples histone acetylation to transcript elongation, especially of the MCL-relevant oncogenes c- lethality, which has therapeutic implication for developing effective combination therapies to achieve long term control of MCL.
MATERIALS AND METHODS:
Reagents. (S)-JQ1 (active enantiomer, hereafter referred to as JQ1) and its inactive enantiomer (R)-JQ1 were developed as previously described 31 . Panobinostat (PS) was kindly provided by Novartis Pharmaceuticals, Inc. (East Hanover, NJ). Ibrutinib, palbociclib, ABT-199, ABT737, and carfilzomib were obtained from Selleck Chemicals (Houston, TX). I-BET151, an orally-available, imidazolonoquinoline-based inhibitor of the BET family of bromodomain-containing proteins was obtained from Xcessbio (San Diego, CA). All antibodies were obtained from commercial sources.
Detailed antibody information is provided in the Supplemental Methods.
Cell lines and cell culture. Mantle cell lymphoma cell lines MO2058, JeKo-1, Z-138, and Mino were obtained and maintained as previously described 38 . HS5 cells were obtained from ATCC (Manassas, VA). HK stromal cells were obtained and maintained as previously described 39 .
Assessment of cell proliferation and percentage of non-viable MCL cells. MCL cells (MO2058,
Mino, JeKo-1, and Z138) were plated in 24 well plates (0.25 x 10 6 /mL) and treated with vehicle or JQ1 for 120 hours. Total cell numbers were measured in triplicate every 24 hours with a coulter counter.
For personal use only. on July 15, 2017. by guest www.bloodjournal.org From Cells treated with JQ1 and/or ibrutinib were assessed for cell viability by PI staining and flow cytometry. All of these studies were performed, as previously described 38, 39 . Treatment with I-BET151 also dose-dependently induced apoptosis of the cultured MCL cells ( Figure   1D ). Notably, treatment with JQ1 caused loss of viability of primary MCL cells purified from the lymph nodes of patients with MCL ( Figure 1E ). As shown in Figure 1F Figure 2A ) 36, 37 . This was also associated with a reduced occupancy of RNAP2 on the promoters of MYC and BCL2 ( Figure 2B ). Based on this, we evaluated the alterations in the mRNA levels in the MCL MO2058 cells, utilizing gene expression microarray (GEM) analysis ( Figure   2C and Supplemental Figure 2A ). Following treatment of MO2058 cells with JQ1 for 8 hours, the expression levels of c-MYC, CDK4, BCL2 and CDK6 declined while HEXIM1 levels increased ( Figure   2C ). In addition, the heat map of the gene expression alterations showed that the mRNA expression of more genes was increased, as compared to the number of genes whose mRNA expression was down regulated (Supplemental Figure 2A) . The fold-change of the thirty most altered mRNA expressions is shown in Supplemental Table 1 . Datasets of genes with the altered expression profile derived from the GEM analyses were imported into the Ingenuity Pathway Analysis (IPA) Tool (Ingenuity H Systems, Redwood City, CA) 39 . Within this gene list, IPA identified the top-five most perturbed gene networks in the MO2058 cells following treatment with JQ1 and assigned a score for these associated network functions (Supplemental Table 2 ). The score (e.g., a score of 57) assigned by the IPA indicates the probability (1 in 10 57 ) that the focus-genes in the dataset are grouped together in a perturbed network
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For personal use only. on July 15, 2017. by guest www.bloodjournal.org From due to random chance alone. Additionally, the most differentially expressed genes were assessed for pathway enrichment utilizing KEGG/Reactome pathway analysis. The top 20 significantly altered pathways in MO2058 cells identified following JQ1 treatment are listed in the Supplemental Table 3 .
These two distinct analyses show similar pathway perturbations due to JQ1 treatment. Next, the qPCR analysis utilizing c-MYC, CDK6 and BCL2-specific TaqMan real-time PCR probes showed that JQ1 treatment attenuated the mRNA expression of c-MYC, CDK6 and BCL2 in the MO2058 cells ( Figure   2D Figure   3C and Supplemental Figure 3B ). In contrast, JQ1 simultaneously induced the expression of HEXIM1 in the MCL cells ( Figure 3C ). Treatment with JQ1 also attenuated the protein levels of the anti-apoptotic XIAP and Bcl-xL proteins in the MCL cells ( Figure 3D and Supplemental Figure 3C ) 41 . BTK is also known to be activated by NFκB and shuttles between the nucleus and cytoplasm 42, 43 . Consistent with this, JQ1-mediated NFκB inhibition attenuated BTK levels both in the nucleus and cytoplasm ( Figure   3B ), as well as reduced the p-BTK levels in the Mino cells ( Figures 3B and 3D ). Similar effects of JQ1
were observed in MO2058 cells ( Figure 3D ). Treatment with I-BET151 also reduced BTK and p-BTK levels in Mino cells (Supplemental Figure 3D) . Notably, co-treatment with the proteasome inhibitor carfilzomib did not restore JQ1-mediated attenuation of BTK and MYC levels, thereby arguing against their degradation by the proteasome (Supplemental Figure 3E ). Figure 7H and 7I) . Notably, as shown in Figure 6D , cotreatment with PS and JQ1 also synergistically induced apoptosis of Mino/IR cells. Next, we determined the effect of co-treatment of JQ1 with palbociclib (a CDK4 and CDK6 inhibitor) or with the BCL2
antagonist ABT-199 45, 46 . Co-treatment with JQ1 and palbociclib or ABT737 or ABT-199 was Figure 6B and 7J). However, co-treatment with JQ1 and ibrutinib lacked synergy against Mino/IR cells (data not shown). We next determined whether pre-treatment with PS, palbociclib and ABT-199 lowers the threshold for ibrutinib-induced apoptosis of Mino/IR cells. We did not observe any significant effect of the pre-treatment with these agents on ibrutinib-induced apoptosis of Mino/IR cells (data not shown). Notably, co-treatment with JQ1 and ABT-199 or palbociclib was also synergistically lethal against primary MCL cells ( Figure 7A and 7B) . Collectively, these findings demonstrate that treatment with the BA JQ1 sensitizes MCL cells to not only HDAC inhibitor but also to CDK4/6 and BCL2 antagonists.
DISCUSSION:
Here, we demonstrate that, by inhibiting the activity of the BET protein BRD4 and the resulting inhibition of NFκB, treatment with a BA attenuates the expression of several NFκB-activated progrowth and pro-survival genes, including BTK, in MCL cells. This results in the BA-mediated growth inhibition and apoptosis of MCL cells. Our findings also show that co-culture with lymph node or bone marrow stromal cells reduced BA-induced lethality of MCL cells. Whereas treatment with ibrutinib is highly effective in inducing remissions in a majority of patients, primary refractoriness or relapse with resistant disease is a common outcome in patients with MCL. We also demonstrate here that cotreatment of MCL with the BA JQ1 and ibrutinib exerts synergistic in vitro lethality and in vivo activity against MCL cells. Additionally, our findings also highlight for the first time that, while treatment with JQ1 alone is also active, co-treatment with JQ1 and panobinostat (PS), palbociclib or ABT-199 is synergistically lethal against cultured MCL cells that display in vitro resistance to ibrutinib. 
